(Q36299958)

English

Alefacept: a safety profile

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

title

Alefacept: a safety profile (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

13 August 2017

Noah Scheinfeld

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

published in

Expert Opinion on Drug Safety

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

volume

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

page(s)

975-985

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

cites work

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.4.6.975

retrieved

21 January 2018

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.4.6.975

retrieved

21 January 2018

Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.4.6.975

retrieved

21 January 2018

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.4.6.975

retrieved

21 January 2018

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14740338.4.6.975

retrieved

21 January 2018

Identifiers

DOI

10.1517/14740338.4.6.975

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

PubMed publication ID

16255657

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16255657

retrieved

13 August 2017

(Q36299958)

Alefacept: a safety profile

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)